BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $63.00 price target on 4D Molecular Therapeutics (NASDAQ: FDMT).

The analyst commented, "4D-710 data continue to show strong saturated CFTR protein expression but triggered investor questions/concerns around: (1) whether 1E15vg is the optimal dose, specifically if it's efficacious/ durable enough and if safety signals seen with 2E15vg could also emerge with 1E15vg; (2) lack of clear FEV1 improvement despite CFTR saturation. Note (i) previous Trikafta data show significant (10%+) FEV1 improvement even with 90% FEV1 baseline; (ii) high-baseline patients could go beyond 100% FEV1 values (assuming 4D-710 FEV1 effect). We note that 4D-710 isn't a major driver of our FDMT valuation. Maintain OP."

For an analyst ratings summary and ratings history on 4D Molecular Therapeutics click here. For more ratings news on 4D Molecular Therapeutics click here.

Shares of 4D Molecular Therapeutics closed at $22.57 yesterday.

You May Also Be Interested In

• BMO Capital on Performance Food Group (PFGC): 'Momentum Building Into F27'
• Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
• Benchmark Reiterates Buy Rating on Global-E Online Ltd (GLBE)